T-cell therapy for EBV-associated nasopharyngeal carcinoma : preparative lymphodepleting chemotherapy does not improve clinical results
Articolo
Data di Pubblicazione:
2012
Citazione:
T-cell therapy for EBV-associated nasopharyngeal carcinoma : preparative lymphodepleting chemotherapy does not improve clinical results / S. Secondino, M. Zecca, L. Licitra, A. Gurrado, I. Schiavetto, P. Bossi, L. Locati, R. Schiavo, S. Basso, F. Baldanti, R. Maccario, F. Locatelli, S. Siena, P. Pedrazzoli, P. Comoli. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:2(2012), pp. 435-441. [10.1093/annonc/mdr134]
Abstract:
Background: We and others have demonstrated that adoptive cell therapy with Epstein-Barr virus (EBV)-specific autologous cytotoxic T lymphocytes (CTLs) may control disease progression in patients with EBV-associated nasopharyngeal carcinoma (NPC). With the aim of favoring in vivo T-cell expansion, we optimized our cell therapy approach by administering higher doses of EBV-specific CTLs, following lymphodepleting chemotherapy. Patients and methods: Eleven patients with EBV-related NPC in whom conventional treatment failed have been enrolled. Patients received nonmyeloablative lymphodepleting chemotherapy consisting of cyclophosphamide and fludarabine. Two doses of autologous EBV-specific CTLs were subsequently infused, 2 weeks apart. Study end points were feasibility and clinical outcome. Results: All patients enrolled completed the treatment and were assessable for analysis. The median dose of CTLs per infusion was 3.7 × 10 8. Therapy was well tolerated, with no severe adverse events ascribable to either chemotherapy or cell therapy. Disease control (defined as either tumor regression or disease stabilization lasting >4 months) was obtained in 6 of 11 patients, in keeping with previously published results. Conclusions: Our data confirm that EBV-specific CTL therapy is safe and associated with antitumor activity in patients with advanced NPC. The use of lymphodepleting chemotherapy before high-dose CTL infusion did not enhance the clinical benefit observed in our previous series.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
cell therapy; cytotoxic T lymphocytes; Epstein-Barr virus; lymphodepletion; nasopharyngeal carcinoma
Elenco autori:
S. Secondino, M. Zecca, L. Licitra, A. Gurrado, I. Schiavetto, P. Bossi, L. Locati, R. Schiavo, S. Basso, F. Baldanti, R. Maccario, F. Locatelli, S. Siena, P. Pedrazzoli, P. Comoli
Link alla scheda completa: